Monday, 26 October 2015 12:28

Heard It Through The Grapevine

Written by

Rumour has it that PBS listing of HCV DAAs is not going to happen this year. It's not official yet, but...

We've started treatment for 5 patients on the transplant list in the last week, all referred from various centers.

If you're F4 waiting might not be your best option.

 

I just sent an email called "There are no words" because... there simply are not.

Dear L,

Please accept my condolences about M's passing and know that the opportunity to meet such a beautiful human being, who became so suddenly unwell, and still, staring death in the eye was weighing up the financial needs of his family with the costs of personal survival touched me.

It helped turned abstract statistics into the thought: "f**k, this is real, people die from this, and I need to help."

I am sorry we were unable to get medications to M in time or at all.

I have copied in Nevil, who was my personal patient zero, challenged me to become involved, and made the connection.

Without both M and Nevil I might have chosen the coward's route and satisfied my conscience with an "It's all too hard" cop out.

I wish more could have been done but it would be fair to say I helped setup FixHepC as a direct result of meeting both Nevil and M.

2 million people from 100 countries have found it.

Last week I started over 50 patients on treatment, including 5 on the transplant list. 

None are M but all have family and friends.

There are no words, but I share this with my patients when faced with similar circumstances:

http://psychcentral.com/lib/the-5-stages-of-loss-and-grief/ 

For some it provides, if not solace, at least understanding of what you must be feeling and comfort that it is normal.

My thoughts are with you.

M's loss will not be in vain.

Kind Regards

James

Tuesday, 20 October 2015 06:04

Bangladesh Is Open For Business

Written by

We have previously tested Incepta's Twinvir and today have received samples of Beacon Pharma's Sofosbuvir, Daclatasvir and Ribavirin products for testing.

We will share the testing results as soon as they are available.

The quality of production of the packaging is extremely impressive, and I must say somewhat better than Sofosbuvir and Ribavirin I have seen from India.

Great packaging won't cure anybody, but it is very encouraging to see such meticulous attention to detail.

Beacon's product even have holographic seals.

Saturday, 17 October 2015 04:18

Who Are We And Where Do We Come From?

Written by

Here is some interesting data from the Google Analytics about the FixHepC visitor demographics.

It's kind of spooky that Google knows your age and sex, but here's their analysis. 

One of the interesting things is that with 1% of the population infected if you consider the impact of spouses and voting age children an organised Hep C "faction" could easily swing 4% of the votes. With an election required by 14th Jan 2017, and therefore likely late next year...

Here is where we all come from - over 100 different countries and counting

 FixHepC visitor geo-location

Friday, 16 October 2015 22:18

ASHM Position Statement On HCV Generics

Written by

NSW Health and ASHM (Australian Society of HIV/HBV/HCV Medicine) have joined forces to issue a position statement titled Importation of Generic HCV Drugs. You can follow the link or read the text below:

08 October 2015

Advice for HCV Clinicians

This communique is for clinicians experienced in the management and treatment of Hepatitis C using Direct Acting Antivirals (DAAs), who may be consulted by their patients who are considering importation of generic DAAs. It assumes an understanding of HCV management and new treatments.

Overview of the current status of DAAs in Australia:

All PBS subsidised treatment for hepatitis C in Australia currently consist of pegylated interferon and ribavirin with the addition of a DAA for genotype 1. These combinations are now not widely used due to side effects, duration of treatment and relatively poor cure rates.

Newer DAA regimens that are interferon-free, well tolerated and have shorter duration of treatment are available in the USA and Europe. They are detailed in the current EASL and AASLD​ evidence-based guidelines.

A number of DAAs have been approved in Australia by the TGA. In 2015, several interferon-free regimens for the treatment of hepatitis C were recommended by the PBAC for inclusion on the PBS, however they are not yet listed. These include:

  • Sofosbuvir + Ledipasvir for genotype 1
  • Sofosbuvir + Daclatasvir for genotypes 1 and 3
  • Sofosbuvir + Ribavirin for genotype 2
  • Sofosbuvir + Pegylated interferon/ Ribavirin for genotype 1
  • Paritaprevir/r + Ombitasvir + Dasabavir (+/- Ribavirin) for genotype 1

Consumers in Australia can currently access DAAs through a number of mechanisms:

  • purchase the drug without subsidy
  • participate in a clinical trial
  • apply under a compassionate access program (limited places)
  • import drugs into Australia for private use under the Personal Importation Scheme​

ASHM recommends that any individual considering DAA therapy discuss their options with a clinician experienced in HCV management and treatment with the new DAAs.

Patients may approach clinicians to write them a script for DAAs so that they can purchase them overseas or via the internet due to their current high cost in Australia without subsidy. In these circumstances, it is important they understand that it is the patient that is the personal importer. The Doctor should document fully the patient’s request and understanding and that the doctor is supporting the patient to personally import the medicines. More information on this process is discussed below. Doctors should not advertise or promote these methods of acquisition to patients.

Evidence for the effectiveness of DAAs:

The efficacy of DAAs in the treatment of hepatitis C has been widely established in the international literature and is detailed in the EASL and AASLD evidence-based guidelines.

Discussing importation of generic DAAs with patients:

Patients are allowed to import up to 3 months of medication for their own use under the Commonwealth Government’s Personal Importation Scheme. It is important that patients know that the safety and quality of medicines purchased overseas or over the internet cannot be guaranteed. 

It is a legal requirement of this scheme that a patient has a prescription from an Australian registered medical practitioner.

Refer patients to the Hepatitis Australia factsheet Importing Medicines into Australia (May 2015).​

Establishing HCV status:

When a patient requests a script for a generic DAA, it is essential to establish their current HCV status. This should be done using a conventional blood sample and laboratory testing.

Current HCV infection is confirmed when the test results are HCV antibody positive and HCV RNA is positive.

Patient HCV assessment:

Once the presence of chronic HCV (HCV RNA +ve) has been confirmed, it is very important in patient assessment to:

- Establish HCV genotype (as this determines the treatment regimen)

- Determine the degree of liver fibrosis (as this influences treatment choice and duration)

- Determine the presence of comorbidities that may affect treatment (e.g. renal disease)

Patients with cirrhosis need ongoing specialist monitoring for complications, including HCC and oesophageal varices. They also need different treatment combinations and more prolonged treatment.

Drug interactions:

The potential for drug interactions with other medication must be considered when DAAs are prescribed. For up to date drug-drug interaction information, go to: http://www.hep-druginteractions.org/ or download the App: HEP iChart.

Compliance with dosing regimen:

It is essential that patients take the right combination of medications for their HCV genotype and stage of fibrosis. They must also take the medication consistently for a sufficient duration in order to optimise the likelihood of viral clearance (SVR or sustained virological response).

Safe injecting strategies:

Patients should be counselled to use safe injecting practices. This will prevent the acquisition of other blood-borne infections and reinfection with hepatitis C.

Monitoring and side effects:

DAAs are generally very safe. Patients should be monitored according to evidence-based guidelines. The key issues are in initial patient assessment (as discussed above).

Patients will also need post treatment assessment including 2 HCV RNAs (PCR) to determine viral clearance. Note that patients with cirrhosis will need lifelong monitoring.

Accessing DAAs through the Personal Importation Scheme

Patients have a number of options to access DAAs, including their purchase in Australia without subsidy. Patients can also personally import the drugs in person or via mail. Details of how to do this can be obtained on the TGA website. A patient can import up to 3 months supply at the one time into Australia using the Personal Importation Scheme.

Generic drugs can be purchased via a number of websites. These drugs have not been evaluated by the TGA. Generic drugs use alternative trade names and packaging and may be a different colour or shape so you must be sure that the drug being purchased is the correct formulation.

Self-importation has some risks associated with it. You do not have the quality protection provided by drugs evaluated and listed on the ARTG. You need to be careful about the veracity of the website. Supply time may vary and the postage time could be delayed if customs investigates the package. Self-importation is legal, but not routine. Having a valid Australian prescription completed by a registered medical practitioner is essential, and completing all the paper work will facilitate the process but patients should allow up to eight weeks for delivery.

How to order Generic DAAs for HCV online:

ASHM does not endorse any specific websites or products. It is up to the individual personally importing the drugs to locate an appropriate website and test the veracity of the supplier. The following are shown as examples only.

FixHepC is a buyers club http://fixhepc.com/getting-treated/how-to-do-it/buyers-club.html that states it will assist with buying, testing and delivery of hepatitis C drugs.

AIDS Drugs Online http://www.aids-drugs-online.com/ has been used to source low-cost generic versions of HIV medications from various overseas manufacturers and they also stock hepatitis C medications. Please be aware that the brand names used on AIDS Drugs Online are not the same as the brands in Australia. For example:

a. Australian brand name: Sofosbuvir

b. AIDS Drugs Online (ADO) brand name: SOFOSBUVIR / Hepcinat

Online suppliers may be only able to supply one of the HCV drugs needed in a regimen, so patients may need to source medicines from more than one source, e.g. the internet and locally through compassionate patient access schemes.

Helpful links:

TGA Personal Importation Scheme https://www.tga.gov.au/personal-importation-scheme

Fix Hep C – website supplying further information on personal importation http://fixhepc.com/

EASL Recommendations on Treatment of Hepatitis C 2015 http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/recommendations-on-treatment-of-hepatitis-c-2015

AASLD HCV Guidance: Recommendations for Testing, Managing and Treating Hepatitis C http://www.hcvguidelines.org/full-report-view​

Hepatitis Australia​ http://www.hepatitisaustralia.com/

For further information:

Contact the ASHM office during office hours on 02 8204 0700.

Friday, 16 October 2015 22:07

Lismore Liver Clinic Now Able To See Patients

Written by

Lismore Liver Clinic is now able to accept referrals for assessment and monitoring of patients accessing generic medications for the treatment of hep C. 

Please note that this does not represent an endorsement of the use of generics, but rather an acceptance that if patients are doing this expert monitoring is within their scope of practice.

The clinic does not assist patients with access to generic HCV medications.

LLC accepts patients living in the NNSWLHD area which basically means south of the QLD border as far as Grafton and inland as far as Tenterfield.

 

The referral details are:

Lismore Liver Clinic
Level 1, 29 Molesworth Street
Lismore NSW 2480

Fax 02 6629 4633 

Thursday, 08 October 2015 10:31

Testing Provisions Patient Safety

Written by

So what is this image? It is a patient safety check. Each coloured line represents a single patient's self imported Sofosbuvir being tested against a reference standard. Yes it's just lines but for each chemical there is a unique NMR signature represented by the spikes in those lines, but let's rewind.....

Back in February when patient zero asked me to help them personally import Hepatitis C medication the conversation went like this:

  • Have you heard about the new DAA medications that cure Hep C?
  • No, I thought the cure was worse than the disease, but it sounds interesting I'll look into it.
  • Ok, so there is a cure, but it's not available (I had some Indian doctor friends check)
  • Ok, so now it is available but it's the wrong treatment for you
  • Ok, so you've found a supplier in China that makes what you need...
  • Ok, so here's the deal:
    • I will prescribe it so you can import it
    • It comes to me first
    • I will arrange to get it tested for you
    • If it passes testing you can take it, if not I will bin it
    • Ok?
  • Yes

So the medication arrived, it did pass testing, patient zero took it and at 4 weeks the pathology company rang up to say:

  • We think there is a problem with patient zero
  • I thought OMG, I've killed him, he's in liver failure, I'm going to be in so much trouble, but said...
  • Ok, so what's the problem?
  • We think you've switched the blood samples because he used to have Hep C and terrible liver function tests but....
    • Now his viral load is zero and his liver function is normal
  • Hallelujah
  • Yeah, no worries, that's expected, he's on treatment
  • Oh, we don't see many of these...

 So patient zero was really supposed to be a one off and was in fact sworn to secrecy, something he honoured.

The problem was I had asked some expert doctors for their opinion, and when patient zero hit VL=0 they started sending me patients who faced the options of parallel import, interferon or death.

So one patient became several, and several became more. With each passing week more people saying "I'm better" and the validation of VL=0.

While the initial testing was robust the lab that did it was careful to inform us that they were not NATA accredited to do testing, so with that in mind we went in search of a NATA accredited lab.

These APIs have also been cross checked in Australia by the NMI (National Measurement Institute) which is NATA (National Association of Testing Authorities) accredited to perform testing. Only the Department of Defense and NMI have NATA accreditation to perform this testing.

Australian NMI NATA Certification Sofosbuvir

Australian NMI NATA Certification Ledipasvir

Australian NMI NATA Certification Daclatasvir

If you happen to be a laboratory looking for real NMR data in multiple solvents, 1H, 13C, 2D, here it all is in one place:

NMR Spectra of Sofosbuvir

NMR Spectra of Ledipasvir

NMR Spectra of Daclatasvir

 

So last night the TPP got the nod in the US. So what is it and what does it mean?

It's supposed to be a free trade agreement, but it apparently has some catches, particularly around medications and patents.

Sadly it's actually impossible to know what it means because to date it's a largely secret deal.

Before it gets the full nod it will need to be approved by our parliament. Then at least it won't be secret.

Depending on the wording it could have an impact on things like FixHepC.

Here's a video about the TPP from Get Up! Click the link to read about it on their site.

 

Sunday, 04 October 2015 23:15

Patient Rights vs Patent Rights

Written by

The thing with Hep C is that it's not about anonymous statistics, it's about real people. Here's the story of one patient, and his wife's journey through Interferon and failure and then to self initiated treatment and cure via the parallel import of generic DAA medications that was published in the Sydney Morning Herald and The Age:

http://m.smh.com.au/national/health/fixhepc-the-buyers-club-for-hepatitis-c-drug-inundated-with-inquiries-20151002-gjzud9.html 

Here is a letter to the editor that did not make the cut

Sunday 27th September 2015

Dear Editor

(Ref: Hepatitis C drug buyers club aims to set up new source of support)

In 1961 JFK uttered the immortal lines "ask not what your country can do for you - ask what you can do for your country".

With the passage of time, the idea we should all put something back in seems increasingly lost.

We have at our fingertips the tools to rid the world of Hepatitis C and are separated from that only by corporate avarice.

Gilead Sciences are asking for more than the entire annual PBS medications budget, used to treat all Australians for all diseases, to treat a single disease forecast to kill half as many people as breast cancer by 2030.

If this medication pricing trend continues unabated you can foresee the day we invent a cure for cancer, but people still die because only a fortunate few can afford access. 

Parallel importing is a tool that has been used before to level the playing field, most notably around the pricing of HIV medications. $1000 a tablet for something that costs $1 to produce and is available overseas for $10 does not make sense.

It’s time to draw a line in the sand and make it clear patient rights deserve equal protection to patent rights.

Kind Regards

Dr James Freeman

 

 

Saturday, 03 October 2015 10:12

The Minimum Cost To Cure Hepatitis C - Revisited

Written by

A patient posted a link that contained a powerpoint presentation from Dr Andrew Hill, PhD. I asked Dr Hill if I could post it here and he said yes.

I turned that into a very quick YouTube movie, so you will probably have to pause it to read it. The attachments include the original PPT (and a PDF version) and two recent papers. Use the readmore to get to them.

 

 

Saturday, 26 September 2015 01:17

FixHepC In The News

Written by

A story about the genesis of this initiative titled Big pharmaceuticals and the Hepatitis C drug trail dubbed a 'miracle cure' ran this morning in The Sydney Morning Herald and The Age.

http://www.smh.com.au/nsw/big-pharmaceuticals-and-the-hepatitis-c-drug-trail-dubbed-a-miracle-cure-20150924-gjtupf.html

There is also another story in the Sydney Morning Herald specifically about the FixHepC Buyers Club called Hepatitis C drug buyers club aims to set up new source of support.

http://www.smh.com.au/national/health/hepatitis-c-drug-buyers-club-aims-to-set-up-new-source-of-support-20150924-gjts1t.html

 

Tuesday, 22 September 2015 12:37

Hep C drugs queue just gets longer

Written by

Hepatitis Australia is using new data released from the Kirby Institute today showing only one per cent of people with hep C received treatment last year to push the government to list new hep C drugs without delay.

"It's time for action," said Kevin Marriott, Hepatitis Australia Acting CEO. "It's time of the federal government to make new therapies widely available, increase liver clinic capacity, upscale hepatitis C treatment and prevention programs and transform the lives of thousands of Australians."

New surveillance data from the Kirby Institute estimated some 230,470 people had chronic hepatitis C infection at the end of 2014. Around 80 percent had early to moderate fibrosis and 19 percent had severe fibrosis or hepatitis C related cirrhosis.

The estimated number of people with severe liver disease/hepatitis C related cirrhosis has more than doubled in ten years, according to the data.

Head of the viral hepatitis clinical research program at the Kirby Institute Professor Greg Dore said that without significant improvement in hepatitis C treatment rates, Australia would see a 245 percent increase in the rates of liver cancer and 230 percent increase in hep C-related deaths by 2030.

"Thousands of Australians are queuing up waiting for new medicines to be PBS listed. These treatments provide one of the great breakthroughs in clinical medicine in recent decades, with enormous potential to improve the lives of people living with hepatitis C," Professor Dore said.

Four new hep C medicines - Gilead's Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir), BMS's Daklinza (daclatasvir)and AbbVie's Viekira Pak (paritaprevir with ritonavir, ombitasvir and dasabuvir plus ribavirin) - have been recommended for PBS listing but price negotiations with sponsors are ongoing. Professor Dore said previously, he suspected listing is more likely for sometime in 2016.

Mr Marriott said there is compelling evidence for the new medicines to be listed without delay before people progress to serious liver disease and die.

"Interferon-free therapies will allow the vast majority of people living with the hepatitis C virus to be cured, even where treatment has failed previously and without the terrible side-effects of existing treatments."

Michelle Lam

Originally published in Pharma in Focus. Reproduced with permission.

Monday, 21 September 2015 08:53

Hep C Buyers Club In TGA Sights

Written by

It has always been a worry that the powers that be may not like the idea of patients parallel importing life saving medications.

The Buyers Club has been active for less than 24 hours and already it seems the battle lines are being drawn: http://www.pharmainfocus.com.au/

The TGA has a job to do, and that is to ensure the medications available to Australian's are safe and useful. Why they let Chemist Warehouse sell bottles of water and call them homeopathic melatonin is beyond me but that's another story.

My job as a doctor is to treat patients with medicines that work.

I'm hopeful that the TGA will continue to respect your personal right to source medication from places where it is available at an affordable cost, rather than abuse its power to prevent that.

This could turn out to be the first big crisis for the Turnbull government - protect the interests of Gilead or those of ordinary Australians.

We will keep you posted as updates come to hand.

 

 

Wednesday, 16 September 2015 01:12

PBAC 2015

Written by

In the last blog reference was made to the failed 2014 PBAC submission, simply because I could not find the PBAC outcome. Somebody has been kind enough to flag my attention to the PBAC 2015 recommendation papers which you can read here:

Sadly the original analysis still largely holds. In no particular order, here are some key points for patients to consider.

Rationing

Treatment criteria: Must be treated in an accredited treatment centre.

So the same Hep C clinic waiting list system will continue.

Patient Treatment Targets

6.26 The PBAC recalled that for the submissions for boceprevir and telaprevir the ICER range presented for a time horizon of 30 years was $15,000/QALY - $45,000/QALY. The PBAC noted, though the prevalent CHC population was approximately 230 000 patients, that approximately 60 000 patients could be treated within the estimated health system capacity over 5 years

Here is a table of the targets:

Year 1

Year 2

Year 3

Year 4

Year 5

6,600

9,900

15,000

15,000

15,000

With over 10,000 new infections a year we don't even make headway until year 3 at which stage we will only be reducing the number of people with Hep C by 5,000 a year.

Harvoni will only be for GT1 and for all other Genotypes Sovaldi is approved for use with PEG/Ribavirin or Ribavirin

The proposed treatment regimens for patients with different genotypes

Genotype

Treatment duration

Treatment regimen

Treatment-naïve (no prior treatment with interferon)

1, 4, 5, 6

12 weeks

SOF12 + PR12

2

12 weeks

SOF12 + R12

3

12 weeks

SOF12 + PR12

24 weeks

SOF24 + R24

Treatment-experienced (prior therapy with an interferon based regimen)

2

12 weeks

SOF12 + R12

3

12 weeks

SOF12 + PR12

24 weeks

SOF24 + R24

                  SOF = sofosbuvir; PR = peginterferon and ribavirin; R = ribavirin

                  Source: Compiled during the evaluation

Price

Although PBAC have redacted some numbers they have not redacted enough:

1.1 Taking account of the proposed drug prices, treatment targets in the Fourth National Hepatitis C Strategy and assuming that care continues to be delivered through specialist treatment centres, DUSC estimated the following number of patients of all genotypes would be treated over the first five years of listing at a net cost to the PBS/RPBS of approximately $3 billion over five years.

Over 5 years, it is estimated that approximately 61 500 patients would be treated....

So the whispers of France's 41,000 ($65,000 AUD) price appear correct - it's at least $50k a patient to take 61,500 over 3 billion.

Patient Subsidy Scheme

Here's a thought.

Rather than fund this through the PBS if the government gave patients $1/2 a billion in direct subsidies (@$2000/head) we could treat everyone in the community using generic imports and GPs to make it happen. At that point we would have effectively no hep C in the environment, new infection rates would fall towards zero because IVDUs would struggle to find an infected needle to share, and as a country we would be $2.5 billion dollars better off.

We could almost put an end to Hep C by this time next year.

We should have massive factories making this stuff and distribute it like polio vaccine - to everyone, everywhere.

How about it Malcolm? Now that would really be leadership...

Sunday, 13 September 2015 00:03

PBAC, the PBS and Rationing

Written by

In Australia there has been optimism about the PBACs decision to recommend that Hep C treatments are put on the PBS.

Some people seem to think that what this means is that these new medications may well be widely available at affordable prices.

Sadly that is unlikely to be the case, for a number reasons, but first a bit of background.

To get a new drug to market a drug company needs to find it, and then test it in various ways. Testing progresses through a number of stages until  there is enough confidence to test it in humans through phase 1, 2 and 3 trials. At each stage more people take the medication. Once the trails conclude the drug company goes to the regulator and says "here is the evidence it works, we now want to sell it". If it all stacks up the regulator - TGA, FDA, EMA, etc grants what is called "marketing approval".

At this point the drug company starts advertising it to doctors and a doctor can write a script for it. Prices are typically very high as the drug company tries to recoup their development expenses.

Many countries have various forms of medication subsidy programs to provision access to expensive medicines for patients that could not afford to pay for them themselves.

The PBAC and The PBS

In Australia our medication subsidy program is called the Pharmaceutical Benefits Scheme (PBS). Getting a medication listed on the PBS is something of "The Holy Grail" for a drug company because now they can continue to charge a high price but the patient pays a much lower price and the PBS pick up the balance of the cost. In the the 2013/14 financial year PBS medication cost $8,837,605,701 with the Government paying $7,292,550,961 (83%) and patients contributing $1,545,054,740 (17%)

http://www.pbs.gov.au/statistics/2013-2014-files/tables-2-2a.pdf

To get on the PBS a drug company needs a recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) so the conversation goes like this:

Big Pharma: "Hey we've got this great drug it does this...."

PBAC: "Great, how much is it?"

Big Pharma: "Well you will save $X so we think $X x 90% would be fair"

PBAC: "You're dreaming, sharpen your pencils and come back when you're serious"

Now this cycle of price negotiation proceeds slowly because the PBAC only meets 3 times a year.

Looking at Hep C drugs we've seen this happening and the PBAC has decided that the price has been reduced enough that the cost-benefit analysis stacks up.

A more in depth analysis of this process is here on http://theconversation.com/why-medicines-take-so-much-time-to-get-listed-on-the-pbs-10902.

So what happens next?

First a firm price needs to be agreed. Rumour has it that price will be France's 41,000 Euro price (currently around $65,000 AUD). To treat all 233,000 Australians with this medication at that price would see a bill of around $15 billion. That's around twice what our Government spends on all the medications subsidised by the PBS each year so do the political math about a Government on the one hand saying "Hey we need a co-pay to save $1 billion", and on the other, "but we want to spend $15 billion over here".

Anyway a positive PBAC recommendation goes to Cabinet for the yay or nay.

Not everything gets the nod at Cabinet, but let's simply assume it does. What will that PBS approval look like for patients?

Not great is the answer, because it will be rationed.

These medications are simply way to0 expensive not to ration and everything else on the PBS at similar price points is heavily rationed.

Here is the rejected PBS application (the one that got the PBAC nod is not, as far as I can find, published yet):

http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2014-07/sofosbuvir-psd-07-2014.pdf

1 Purpose of Application

1.1 Section 100 (Highly Specialised Drugs Program), Authority Required (STREAMLINED) listing for sofosbuvir for the treatment of chronic hepatitis C (CHC) in the following populations:

  • Treatment naïve, Genotype 1-6;
  • Treatment naïve, Genotype 1-3 in patients unsuitable for treatment with interferon based therapy;
  • Treatment experienced, Genotype 2 and 3; and,
  • Treatment experienced, Genotype 2 and 3 in patients unsuitable for treatment with interferon based therapy.

1.2 The submission had not requested listing for genotypes 4, 5 or 6 treatment naïve patients who are unsuitable for interferon (IFN) therapy, nor for genotypes 1, 4, 5 or 6 for patients who are treatment experienced.

There are a series of take home points from this:

  1. Gilead's earlier application excluded a lot of patients
  2. Once you progress past section 1 you will see further exclusions like "Patient must have compensated liver disease"
  3. This is an S100 application and that in itself restricts access even further

So what is S100?

When a medication is listed on the PBS it can be in any of the following broad categories (there are some further nuances I'm ignoring):

  • General benefit - anyone can have it, any GP can prescribe
  • Restricted benefit - anyone with a certain condition can have it, any GP can prescribe
  • Authority required - anyone with a certain condition can have it, and for most (but not all) a GP can still prescribe it but:
    • Government approval is required
      • Streamline (done by software)
      • Phone (requires a doctor to call and ask for permission)
  • S100
    • Like a phone authority where only patients who meet the criteria can have it, but with the added kicker that.....
    • Only a small group of doctors with formal S100 prescriber rights for that medication can prescribe it

A cynic would call this rationing by stealth.

Hep C and HIV are similar so let's look at HIV medication to see what a PBS listing is likely to look like.

Here is an indication of what the doctors need to do to be able to prescribe S100 HIV medications: http://www.ashm.org.au/hiv/prescriber-programs.

And here is the wording on the restrictions for prescribing a common HIV medication called Atripla (Also a Gilead product) when it was first listed http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2011-11/pbac-psd-tenofovir-nov11

Restriction: Section 100 listing

Public Hospital Authority Required (STREAMLINED)

Private Hospital Authority Required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy of HIV infection.

Now you can buy Atripla privately for $1186.39 for 30 tablets from Chemist Warehouse so it's at least 20 times cheaper than Harvoni, so you could reasonably expect it to have less restrictions on its prescription. In fact, that has happened, because the restrictions around CD4 count have been removed since the original recommendation back in 2011.

So what does it all mean?

Even when the new Hep C medications are PBS listed the chances are better than fair that you personally won't be able to get them because either a) you won't be eligible or b) you won't be able to see an approved S100 prescriber who might reasonably be expected to be the same people running the Liver Clinics and maybe Gastroenterologists and Infectious Disease Specialists being "grandfathered in" without any special training. That's the typical approach.

As time passes, prices will fall, and the rationing will be eased, but even at the $1186 a month price point for medications like Atripla significant restrictions continue to exist.....

You would have to be a rampant optimist to believe historical PBS listing practices will not be applied to Hep C medications.

That's not to say you should not, or cannot afford to wait. It is to say that if historical patterns are followed, for most people, waiting years to access treatment is going to be inevitable.

If it was me I know what I'd do, but everybody is different and YMMV.

Thursday, 10 September 2015 13:05

Are Gilead Really Bastards?

Written by

So I received an email pointing out that you can make these new medications for $1 a dose.

The question, not really a question, more of a talking point, was this:

Hill et al 2014: US$2000 might seem dirt cheap for a 12-week course of meds to clear Hep C (compared to Gilead’s US$84,000), but this excellent study provides a reality check, finding that the production costs at scale for sofosbuvir is $68-136, and for daclatasvir $10-30. They didn’t assess ledipasvir.

So here's what I replied:

To be fair to Gilead,

Yes the cost to produce a single dose is circa $1 but.....

It's not unreasonable that these dudes turn a profit. At the end of the day if drug companies don't make a profit they go bankrupt because they can't pay their bills.

155,000,000 people have Hep C. So let's say that 1% are willing/able to pay That's only 1.5 million. Now Gilead paid $11 billion for Pharmaset, set let's ignore production costs for a moment.

Gilead actually need those 1.5 million to pay just over $7,500 each to get to $11 billion and break even.....

Now this is not to defend Gilead's practices but simply to point out all businesses have to amortize fixed costs, so sure you can make it for $1 but you've got (in this case) ~ $75 fixed costs per dose

To get the fixed costs down to $1000 per patient you need to treat 11,000,000 people.

Personally I'd rather see all 155,000,000 treated.

So here is my open letter to Gilead:

Dear Gilead,

With great power comes great responsibility.

You have the capacity to make a difference, make a profit, or both.

You have already amortized your investment and made a 100% profit on your $11 billion investment.

Doubling your money in a couple of years is good so be happy.

How about you consider limiting your future profits to 1000% and you make Harvoni available for $10 a tablet worldwide?

You know, like you do in Egypt?

You could save about 1/2 a million lives a year.

Just in case you were wondering, that's 1 person a minute dying for lack of access to treatment.

Kind Regards

Dr James Freeman on behalf of 155,000,000 fathers, mothers, sons and daughters.

PS: Alternatively parallel importing will undermine your market and patients will access medication at this price point anyway. That will be sad for you because your potential 1000% profit will go to people who did not take the risks you did with your investment. Bastardos! Why not undercut them and get worldwide adulation?

PPS: If you don't believe this is going to happen look to history - parallel importing of HIV medication into Africa and the Dallas Buyers Club spring to mind.

Sunday, 06 September 2015 00:06

Factory making fake Hepatitis C drug raided

Written by

 Assisted by the Federal Investigation Authority (FIA), personnel of the Drug Regulatory Authority of Pakistan (DRAP) raided one of the local industries in Islamabad’s Kahuta industrial area here Saturday, leading to the discovery of unlawful manufacturing of Sofasbuvir tablets, which are used for the treatment of Hepatitis C....

Readmore at http://www.thenews.com.pk/Todays-News-6-304343-Factory-making-fake-Hepatitis-C-drug-raided

 

 WHO today published the new edition of its Model List of Essential Medicines which includes ground-breaking new treatments for hepatitis C.

http://www.who.int/mediacentre/news/releases/2015/new-essential-medicines-list/en/ 

On the 20th May 2015 the Medicines and Healthcare products Regulatory Agency in the UK issued a Drug Safety Update titled:

Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone.

Wednesday, 08 July 2015 06:40

Sofosbuvir Reference NMR Comparison

Written by

Today we compared a new batch of Sofosbuvir and Ledipasvir to our reference sample data and found it consistent.

It's reassuring to see the consistency.

Wednesday, 10 June 2015 06:40

Sofosbuvir Ledipasvir NMR and Mass Spec

Written by

We were quite excited to see the first shipment of Chinese sourced Sofosbuvir and Ledipasvir. A white powder and and off white powder, but what would the NMR show? Here's the NMR for Sofosbuvir which is right on the money.

Ledipasvir: mass [M+H] + 889.4195 ( < 2 ppm error)

  • molecular formula - C49H54F2N8O6

Sofosbuvir: mass [M+H] + 530.1699 ( < 0.2 ppm error)

  • molecular formula - C22H29FN3O9P
Friday, 03 July 2015 06:40

Newsflash PBAC

Written by

In Australia the PBAC has voted to recommend the inclusion of sofosbuvir in the PBS. This could mean that this vital medication becomes available at affordable prices in Australia, however it's also possible Cabinet will reject this given that inclusion in the PBS could see the current $10 billion spent by the government on all PBS medications blow out to $30 billion. We will keep you posted as to developments.

Here is the PBAC Recommendation

For now the options remain to either pay $100,000 for a private prescription, wait and see, or seek out treatment yourself.

Page 3 of 3